<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-2391</journal-id>
<journal-title><![CDATA[Acta pediátrica de México]]></journal-title>
<abbrev-journal-title><![CDATA[Acta pediatr. Méx]]></abbrev-journal-title>
<issn>0186-2391</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Pediatría]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-23912018000300250</article-id>
<article-id pub-id-type="doi">10.18233/apm39no3pp250-2551609</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Síndrome urémico hemolítico atípico. Reporte de caso y revisión de la bibliografía]]></article-title>
<article-title xml:lang="en"><![CDATA[Atypical hemolytic uremic syndrome. Case report and review of the literature.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez-García]]></surname>
<given-names><![CDATA[Raquel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rebolledo-Zamora]]></surname>
<given-names><![CDATA[Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vázquez-Perdomo]]></surname>
<given-names><![CDATA[María del Rosario Mayela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bojórquez-Ochoa]]></surname>
<given-names><![CDATA[Aurora]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Corcuera-Delgado]]></surname>
<given-names><![CDATA[Celso Tomá&#769;s]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,departamento de Nefrología pediátrica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,aff2  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,aff3  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,departamento de Nefrología pediátrica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,al departamento de Anatomía patológica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<volume>39</volume>
<numero>3</numero>
<fpage>250</fpage>
<lpage>255</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-23912018000300250&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-23912018000300250&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-23912018000300250&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: el síndrome urémico hemolítico, en su variedad atípica, es una microangiopatía trombótica poco frecuente, con elevadas morbilidad y mortalidad si no se establece el diagnóstico oportuno que permita el tratamiento específico adecuado.  Caso clínico: paciente con diagnóstico confirmado de síndrome urémico hemolítico atípico tratado con eculizumab con remisión total y evolución clínica satisfactoria. La sospecha diagnóstica es importante para que el tratamiento sea temprano y específico y el pronóstico favorable.  Conclusión: el caso aquí reportado es ilustrativo de la presentación clínica del síndrome hemolítico urémico atípico. Su evolución fue tórpida, a pesar del tratamiento con infusión de plasma y plasmaféresis y su remisión total con eculizumab. En México se han confirmado pocos casos, sólo en algunos se ha administrado el tratamiento específico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: The hemolytic uremic syndrome in its atypical variety is a rare thrombotic microangiopathy, with high morbidity and mortality if a timely diagnosis is not available to allow an adequate specific treatment.  Clinical case: Patient with a confirmed diagnosis of atypical hemolytic uremic syndrome treated with eculizumab with total remission and satisfactory clinical evolution. Diagnostic suspicion is important for early and specific treatment and favorable prognosis.  Conclusion: The case reported here is illustrative of the clinical presentation of the atypical haemolytic uraemic syndrome. Its evolution was torpid, despite the treatment with plasma infusion and plasmapheresis and its total remission with eculizumab. In Mexico, few cases have been confirmed, only in some cases has the specific treatment been administered.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[síndrome urémico hemolítico atípico]]></kwd>
<kwd lng="es"><![CDATA[microangiopatía trombótica]]></kwd>
<kwd lng="es"><![CDATA[eculizumab]]></kwd>
<kwd lng="en"><![CDATA[atypical hemolytic uremic syndrome]]></kwd>
<kwd lng="en"><![CDATA[thrombotic microangiopathy]]></kwd>
<kwd lng="en"><![CDATA[eculizumab]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Constantinescu]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Bitzan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-entero-pathic hemolytic uremic syndrome causes and short-term course]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2004</year>
<volume>43</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>976-82</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laurence]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atypical hemolytic uremic syndrome (aHUS) making the diagnosis]]></article-title>
<source><![CDATA[Clin Adv Hematol Oncol]]></source>
<year>2012</year>
<volume>10</volume>
<numero>10 Suppl 17</numero>
<issue>10 Suppl 17</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Nester]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Syndromes of thrombotic microangiopathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>371</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>654-66</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Noris]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Caprioli]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bresin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2010</year>
<volume>5</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1844-59</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fremeaux-Bacchi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Fakhouri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Garnier]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetics and outcome of atypical hemolytic uremic syndrome a nation wide French series comparing children and adults]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2013</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>554-62</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ohanian]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cable]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Halka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome]]></article-title>
<source><![CDATA[Clin Pharmacol Adv Applications]]></source>
<year>2011</year>
<volume>3</volume>
<page-range>5-12</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mannucci]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Cugno]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome Laboratory weapons and their impact on treatment choice and monitoring]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>2015</year>
<volume>136</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>851-4</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sperati]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Moliterno]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thrombotic microangiopathy focus on atypical hemolytic uremic syndrome]]></article-title>
<source><![CDATA[Hematol Oncol Clin North Am]]></source>
<year>2015</year>
<volume>29</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>541-59</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nester]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atypical hemolytic uremic syndrome what is it, how is it diagnosed, and how is it treated?]]></article-title>
<source><![CDATA[Hematology Am Soc Hematol Educ Program]]></source>
<year>2012</year>
<volume>2012</volume>
<page-range>617-25</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Erlic]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffmann]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome]]></article-title>
<source><![CDATA[Ann Hum Genet]]></source>
<year>2010</year>
<volume>74</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-26</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Noris]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Remuzzi]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atypical hemolyticuremic syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2009</year>
<volume>361</volume>
<page-range>1676-87</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caprioli]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Noris]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brioschi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetics of HUS the impact of MCP, CF, and IF mutations on clinical presentation, respond to treatment, and outcome]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2006</year>
<volume>108</volume>
<page-range>1267-79</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Legendre]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Licht]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Muus]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Terminal complement inhibitor eculizumab in atypical hemolyticuremic syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>368</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2169-81</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loirat]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Kakhouri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ariceta]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An international consensus approach to the management of atypical hemolytic uremic syndrome in children]]></article-title>
<source><![CDATA[Pediatr Nephrol]]></source>
<year>2016</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15-39</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sellier-Lerclerc]]></surname>
<given-names><![CDATA[Al]]></given-names>
</name>
<name>
<surname><![CDATA[Fremeaux- Bacchi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Dragon-Durey]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[French Society of Pediatric Nephrology Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome]]></article-title>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>2007</year>
<volume>18</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2392-400</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
